Eric WinerAssociate Professor of Medicine (Clinical)
Dr. Winer received his MD from the University of North Carolina School of Medicine in 1999. He then completed his internship and residency in Internal Medicine at Tufts Medical Center and remained to complete his Hematology/Oncology fellowship. Currently he is an Assistant Professor at the Warren Alpert School of Medicine at Brown University. His clinical and research focus is in Malignant Hematology, particularly novel therapies in the treatment of leukemias, lymphomas, and multiple myeloma. He also has been active in retrospective studies in regards to treatment, epidemiology and prognostic criteria of hematologic malignancies.
Dr. Winer's main research interests involve novel therapeutics in the treatment of leukemia, lymphoma, and multiple myeloma through clinical trials. He also is involved in numerous retrospective endeavors to look at prognostic factors in the treatment of hematologic malignancies. He most recent research endeavors use large database analyses and meta-analyses to evaluate treatment efficacy and epidemiologic factors in hematologic malignancies.
Co-nvestigator. LS-P-CASTOR: A Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects with Relapsed or Refractory Multiple Myeloma. Sponsored by Janssen Pharmaceuticals
Co-Investigator: TRC117146: Testing Eltrombopag versus Placebo in Patients with Acute Myelogenous Leukemia (AML) who receive chemotherapy with daunorubicin plus cytarabine. Sponsored by GlaxoSmithKline
Principle Investigator: TRC112765: A randomized, blinded, placebo-controlled, two-phase, sequential cohort, dose finding study to assess the safety and efficacy of an oral thrombopoietin receptor agonist, eltrombopag administered to patients with solid tumors receiving gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin. Sponsored by GlaxoSmithKine.
Principle Investigator: BRUOG NHL227: Ofatumumab and bortezomib for patients with low-grade B-cell non-Hodgkin’s lymphoma that relapsed 6 monts beyond a rituximab-containing regimen. Sponsored by the Brown University Oncology Group. Funded by GlaxoSmithKline and Millennium Pharmaceuticals.
Co-Investigator: FOLBRITe: A multicenter, open label, phase II study of Bendamustine and Rituximab followed by 90-yttrium (Y) Ibritumomab Tiuxetan for untreated follicular lymphoma. Funded by Spectrum Pharmaceuticals.
May 2004 ASCO Merit Scholar, American Society of Clinical Oncology
2010 Healthcare Professional of the Year, Leukemia Lymphoma Society,
2009-2013 Certificate of Recognition for Exemplary Teaching, Warren Alpert Medical School, Hematology course
2012 Educator of the year, Brown Hematology/Oncology Fellowship, Warren Alpert Medical School
2013 Beckwith Family Award for Outstanding Teaching, Department of Medicine, Warren Alpert Medical School
2014 Dean’s Excellence in Teaching Award, Warren Alpert Medical School of Brown University.
2010-Present Steering Committee, Lymphoma Research Foundation NE rounds
2009-Present Executive Committee, Leukemia & Lymphoma Society, RI chapter
2007-Present Alliance (Cancer and Leukemia Group B)
2006- Present Brown University Oncology Group
2002-Present American Society of Hematology
2003-Present American Society of Clinical Oncology
1999-Present Massachusetts Medical Society
1999-Present Suffolk Medical Society
1995-Present American Medical Association
Small Group Leader; BioMed Pathophysiology, BIOL3672IMF4: Hematology Section, The Warren Alpert Medical School of Brown University (2007-present)